Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thor Medical
Oslo, Norwaythormedical.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Other
01
Overview
Thor Medical supplies alpha-particle emitting radionuclides (notably lead-212, radium-224, and thorium-228) for use in radioligand therapies targeting cancer, with supply agreements with radiopharmaceutical companies whose programs are in late-stage development of tumor-targeted therapeutics using these isotopes[1][3][4].
- Therapeutic areas
- OncologyHematology
- Modalities
- RadiopharmaceuticalAlpha-particle emitter
- Industry
- Chemicals & Materials
02
Partnerships
Multiple radiopharmaceutical companies with late-stage cancer therapeutic candidates (undisclosed)Major European multinational chemical manufacturing company (thorium feedstock supply)Steenkampskraal Holdings Ltd (thorium supply MoU)
Beyond the preview
Go deeper on Thor Medical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thor Medical.